For specialty therapies, adherence is rarely determined by a medication reminder alone.
It is shaped by everything that happens around treatment: how quickly patients get started, whether they understand what to expect, how emerging barriers are identified, and whether the right support reaches them when it matters.
The World Health Organization has long recognized adherence as a multidimensional challenge influenced by patient, therapy, condition, socioeconomic, and health system factors. More recently, research into digital health interventions has reinforced an important point: technology alone does not guarantee better adherence outcomes.
For pharmaceutical manufacturers evaluating digital patient support platforms, the question is therefore bigger than which engagement features are available.
The strongest platforms connect patient behavior, clinical requirements, support services, and real-world data to help patients start, stay on, and safely progress through treatment.
Here are seven capabilities pharma teams should assess when considering patient support programs / platforms.
1. Frictionless Patient Onboarding and Therapy Initiation
Adherence begins before the first dose.
Enrollment, consent, baseline testing, prior authorization, specialty pharmacy coordination, and treatment readiness requirements can all create friction between prescription and therapy initiation.
A digital patient support platform should help coordinate these steps, giving patients and support teams visibility into what has been completed, what is outstanding, and what needs to happen next.
Manufacturers should look for capabilities that can:
- Digitize enrollment and consent
- Track treatment readiness
- Coordinate required pre-treatment steps
- Identify incomplete actions or delays
- Trigger the appropriate next workflow
For complex therapies, improving specialty therapy adherence starts with helping patients successfully reach treatment in the first place.
2. Personalized Support Across the Patient Journey
Not every patient needs the same support at the same time.
A newly prescribed patient may need education and reassurance. Someone entering titration may need support managing expectations or establishing a treatment routine. A long-term patient may need reinforcement to maintain motivation and persistence.
Effective pharmaceutical patient engagement should adapt accordingly.
This aligns with the FDA’s patient-focused approach, which emphasizes meaningfully incorporating patients’ experiences, perspectives, needs, and priorities into decisions related to their health and treatment.
Platforms should therefore be able to personalize education, reminders, check-ins, health tracking, behavioral nudges, and support resources based on where a patient is in their treatment journey and what they need.
The goal is not more communication, but more relevant communication.
3. Behavioral Adherence Support
Knowing that a patient missed a dose is useful.
Understanding why they missed it is valuable.
Forgetfulness, treatment burden, side effects, health literacy, motivation, and disruptions to daily routines can all influence adherence. The WHO identifies factors including motivation, self-efficacy, information, self-management skills, and behavioral support as important considerations in adherence.
Digital patient support platforms should therefore go beyond reminder functionality and help patients establish routines, track progress, build confidence, and receive timely support based on individual barriers.
The distinction matters:
A reminder tells a patient what to do. Behavioral support helps address what may prevent them from doing it.
For manufacturers designing patient support programs, this is the difference between generating digital activity and supporting meaningful behavior change.
4. Real-Time Risk Detection and Intervention
Patient support can become reactive when early signs of risk go unnoticed.
A patient may miss doses, disengage from support, or report worsening symptoms. By the time these signals are recognized, the patient may already be at risk of treatment discontinuation.
Digital platforms create an opportunity to identify those signals earlier by bringing together medication, engagement, symptom, monitoring, and patient-reported data.
The FDA is increasingly exploring how digital technologies can capture behavioral, functional, medication-use, adherence, and patient-reported data outside traditional clinical settings.
For manufacturers, however, collecting more data should not necessarily be the end goal alone. It is leveraging data to prevent risk and/or intervene appropriately.
When a risk signal appears, the platform should be able to initiate the appropriate next step, whether that is additional education, an automated check-in, support-team outreach, or escalation to an HCP.
For treatment outcomes, the critical capability is turning information into timely intervention.
5. Connected Human and Digital Support
Digital support should not replace human support.
It should help determine when human intervention is most valuable.
Some patient needs can be addressed effectively through automated education, reminders, navigation, or AI-supported interactions. Others require a nurse, navigator, case manager, or healthcare professional.
Research evaluating interactive digital adherence interventions has found promising results from approaches that increase patient involvement, build medication-management skills, coordinate adherence care between professionals, and facilitate communication between patients and healthcare providers.
Strong complex therapy support therefore requires both digital and human capabilities.
A platform might automatically reinforce an upcoming medication routine while escalating repeated missed doses or concerning symptom reports to a support professional.
The objective is not automation for its own sake.
It is getting the right support to the right patient at the right time.
6. Integration Across the Specialty Therapy Ecosystem
Patients experience one treatment journey.
Behind that journey, enrollment, lab monitoring, pharmacy services, patient engagement, safety workflows, and human support may all operate through different vendors and systems.
Even when each component works well independently, disconnected systems create blind spots.
When conducting a platform evaluation, manufacturers should therefore assess whether the platform can integrate with:
- Patient support services
- Specialty pharmacies
- Laboratory systems
- HCP workflows
- CRM and EMR systems
- Safety and monitoring workflows
- Patient-facing applications
The goal is not necessarily to replace every existing partner. It is to make those partners operate as a coordinated program.
For specialty therapies, coordination itself is an adherence capability.
7. Real-World Measurement and Continuous Optimization
Launching a patient support program is not the end of the adherence strategy.
It is the beginning of the evidence-gathering process.
Manufacturers need visibility into how patients behave in the real world and which aspects of the program influence those behaviors.
Digital patient support platforms should help teams measure outcomes such as enrollment, time to therapy, engagement, medication adherence, persistence, patient-reported outcomes, monitoring completion, and support interventions.
Patient-reported information is particularly important. The FDA defines patient experience data as information capturing patients’ experiences, perspectives, needs, and priorities, including symptoms, treatment experiences, quality of life, preferences, and outcomes that matter to patients.
But reporting alone is not enough.
The more valuable question is:
What can the program do differently because of what the data shows?
That creates a continuous feedback loop between real-world patient behavior and program strategy.
What Should Pharma Look for in a Digital Patient Support Platform?
In summary, pharmaceutical manufacturers evaluating digital patient support platforms should prioritize seven capabilities:
- Frictionless onboarding and therapy initiation
- Personalized patient support
- Behavioral adherence interventions
- Real-time risk detection
- Connected human and digital support
- Ecosystem integration
- Real-world measurement and optimization
The most important consideration, however, is how those capabilities work together.
A program can have strong patient education, sophisticated analytics, experienced nurses, pharmacy services, and medication tracking and still leave gaps if each capability operates independently.
The better evaluation question is not simply:
What features does the platform have?
It is:
Can the platform understand what is happening across the treatment journey and coordinate what needs to happen next?
For complex specialty therapies, that is increasingly what separates digital engagement from true patient support infrastructure.
Building Connected Patient Support
At RxPx, we believe digital patient support should do more than add another engagement tool to an already complex ecosystem.
RxPx connects patients, HCPs, labs, pharmacies, digital engagement, and human support within one coordinated experience designed around the moments that determine whether patients start, stay on, and safely progress through therapy.
Across RxPx programs, this approach has contributed to 92% adherence in real-world settings and 97% patient engagement through the first 90 days.
For pharmaceutical manufacturers, the opportunity is to move beyond disconnected engagement toward infrastructure that can identify risk, coordinate intervention, and continuously improve how the patient support program performs.
Because adherence is not driven by one reminder, one app, or one service.
It is driven by how well the entire therapy experience works together.
Book a Brand Risk Assessment to identify where gaps in your patient support strategy could put adherence at risk and where a more connected approach could make a difference.
Frequently Asked Questions
What is a digital patient support platform?
A digital patient support platform helps patients navigate treatment through capabilities such as onboarding, education, medication support, symptom tracking, monitoring, and care coordination. For specialty therapies, platforms can also connect HCPs, labs, pharmacies, and support teams around the patient journey.
How can digital patient support platforms improve adherence?
Digital patient support platforms can support adherence by reducing treatment friction, personalizing engagement, reinforcing treatment behaviors, identifying emerging risks, and connecting patients with human support when intervention is needed.
What features matter most for specialty therapy adherence?
Manufacturers should prioritize streamlined therapy initiation, personalized engagement, behavioral support, risk detection, human escalation, ecosystem integration, and real-world measurement.
Why is integration important in patient support programs?
Integration allows information from patients, HCPs, laboratories, pharmacies, and support services to inform the same patient journey. This reduces gaps between systems and helps important events trigger the appropriate next action.
